Birgitte Pedersen et al, Vejle Hospital, Denmark. Patients with colorectal cancer (CRC) face huge challenges in their everyday lives as a result of their condition and treatments.
Discussion of the abstract by Professor Philippe Autier, Vice President, Population Studies, at the International Prevention Research Institute, Lyon, France.
Discussion of the abstract by Dr Zoran Gatalica, Adjunct Professor of Pathology at Creighton University School of Medicine .
by Peter Mas Mollinedo – Improvements in diagnostics and medical treatments mean the number of patients living with cancer is increasing around the world. The World Health Organization… read more.
by Peter Mas Mollinedo reporting on the presentation by Dominique Elias, Gustave-Roussy Institute, Paris, France. – Aggressive complete cytoreductive surgery (CCRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC)… read more.
LM Wiltink, Leiden University Medical Center, the Netherlands; Hans-Joachim Schmoll, Martin Luther University Halle – Wittenberg, Germany. A unique 14-year follow-up study from the universities of Leiden in… read more.
by Esther Drain reporting on the presentation by Dr Timothy Price – A randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated… read more.
Report by Esther Drain – Cetuximab resulted in a significant improvement in survival in TP53 WT, high-risk Rectal Cancer.
Taken from the European Cancer Congress ( ECCO / ESMO / ESTRO ) from the 27th September – 1st October 2013 in Amsterdam.
FDA Highlights by Bruce Sylvester – Researchers report from a phase I clinical trial report that diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy have been successfully reprogrammed… read more.
A newly-described immunodeficiency syndrome of neutrophil defects, bone marrow fibrosis, nephromegaly, and life-threatening infections arises from a genetic mutation that impairs movement of proteins within cells, researchers found.
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
